ES2182897T3 - Regulacion por proteasoma de la actividad de nf-kappa-b. - Google Patents

Regulacion por proteasoma de la actividad de nf-kappa-b.

Info

Publication number
ES2182897T3
ES2182897T3 ES95914075T ES95914075T ES2182897T3 ES 2182897 T3 ES2182897 T3 ES 2182897T3 ES 95914075 T ES95914075 T ES 95914075T ES 95914075 T ES95914075 T ES 95914075T ES 2182897 T3 ES2182897 T3 ES 2182897T3
Authority
ES
Spain
Prior art keywords
activity
proteasome
kappa
regulation
animal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95914075T
Other languages
English (en)
Other versions
ES2182897T5 (es
Inventor
Vito J Palombella
Alfred L Golberg
Thomas P Maniatis
Oliver Rando
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Harvard University
Original Assignee
Harvard University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22782682&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2182897(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Harvard University filed Critical Harvard University
Publication of ES2182897T3 publication Critical patent/ES2182897T3/es
Application granted granted Critical
Publication of ES2182897T5 publication Critical patent/ES2182897T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06078—Dipeptides with the first amino acid being neutral and aromatic or cycloaliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
    • C07K5/06043—Leu-amino acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Detergent Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Distillation Of Fermentation Liquor, Processing Of Alcohols, Vinegar And Beer (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

SE DESCRIBE UN METODO PARA REGULAR LA ACTIVIDAD DE NF- KA}B EN UN ANIMAL, MEDIANTE EL CONTACTO DE LAS CELULAS DEL ANIMAL CON CIERTOS INHIBIDORES DE PROTEASOMAS.
ES95914075T 1994-03-18 1995-03-17 Regulacion por proteasoma de la actividad de nf-kappa-b. Expired - Lifetime ES2182897T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/210,381 US6660268B1 (en) 1994-03-18 1994-03-18 Proteasome regulation of NF-KB activity
US210381 1994-03-18

Publications (2)

Publication Number Publication Date
ES2182897T3 true ES2182897T3 (es) 2003-03-16
ES2182897T5 ES2182897T5 (es) 2006-10-16

Family

ID=22782682

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95914075T Expired - Lifetime ES2182897T5 (es) 1994-03-18 1995-03-17 Regulacion por proteasoma de la actividad de nf-kappa-b.

Country Status (11)

Country Link
US (2) US6660268B1 (es)
EP (1) EP0750507B2 (es)
JP (1) JPH09510710A (es)
AT (1) ATE228002T1 (es)
CA (1) CA2184727C (es)
DE (1) DE69528888T3 (es)
DK (1) DK0750507T4 (es)
ES (1) ES2182897T5 (es)
PT (1) PT750507E (es)
SI (1) SI0750507T2 (es)
WO (1) WO1995025533A1 (es)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6083903A (en) 1994-10-28 2000-07-04 Leukosite, Inc. Boronic ester and acid compounds, synthesis and uses
US6838477B2 (en) * 1995-04-12 2005-01-04 President And Fellows Of Harvard College Lactacystin analogs
US5834487A (en) * 1996-09-24 1998-11-10 Cv Therapeutics Inhibition of 26S and 20S proteasome by indanones
US6271199B2 (en) * 1997-02-15 2001-08-07 Millennium Pharmaceuticals, Inc. Treatment of infarcts
US6831057B2 (en) 1997-10-28 2004-12-14 The University Of North Carolina At Chapel Hill Use of NF-κB inhibition in combination therapy for cancer
US6207412B1 (en) * 1997-11-13 2001-03-27 The Regents Of The University Of California Identification of a G protein-coupled receptor transcriptionally regulated by protein tyrosine kinase signaling in hematopoietic cells
US6075150A (en) * 1998-01-26 2000-06-13 Cv Therapeutics, Inc. α-ketoamide inhibitors of 20S proteasome
US6617171B2 (en) 1998-02-27 2003-09-09 The General Hospital Corporation Methods for diagnosing and treating autoimmune disease
US6838436B1 (en) 1998-07-10 2005-01-04 Osteoscreen Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6902721B1 (en) 1998-07-10 2005-06-07 Osteoscreen, Inc. Inhibitors of proteasomal activity for stimulating bone growth
US6462019B1 (en) 1998-07-10 2002-10-08 Osteoscreen, Inc. Inhibitors of proteasomal activity and production for stimulating bone growth
EP0995757A3 (en) * 1998-08-26 2002-05-22 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
EP0982317A1 (en) * 1998-08-26 2000-03-01 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Bivalent inhibitors of the proteasome
KR20010080267A (ko) 1998-10-20 2001-08-22 밀레니엄 파머슈티컬스 인코퍼레이티드 프로테아솜 억제제 약물 작용을 모니터링하는 방법
US6599710B1 (en) 1999-03-10 2003-07-29 The General Hospital Corporation Treatment of autoimmune disease
US20030165492A1 (en) * 2000-06-08 2003-09-04 Alberto Panerai Method of treatment of alzheimer's disease with a protein extractable from mammalian organs
US7582313B2 (en) 2002-06-27 2009-09-01 The General Hospital Corporation Methods of organ regeneration using Hox 11-expressing pluripotent cells
US7628988B2 (en) 2002-06-27 2009-12-08 The General Hospital Corporation Methods and compositions for treating type 1 diabetes
EP1565193B1 (en) * 2002-11-06 2013-04-24 Dana-Farber Cancer Institute, Inc. Compositions for treating cancer using proteasome inhibitor PS-341
ES2542328T3 (es) 2002-12-06 2015-08-04 Millennium Pharmaceuticals, Inc. Métodos para la identificación, evaluación y tratamiento de pacientes con terapia de inhibición del proteasoma
US7223745B2 (en) 2003-08-14 2007-05-29 Cephalon, Inc. Proteasome inhibitors and methods of using the same
US7576206B2 (en) 2003-08-14 2009-08-18 Cephalon, Inc. Proteasome inhibitors and methods of using the same
CA2558618A1 (en) * 2004-02-06 2005-08-25 The University Of Chicago An anti-inflammatory, cytoprotective factor derivable from a probiotic organism
WO2006062732A2 (en) * 2004-11-19 2006-06-15 Synta Pharmaceuticals Corp. Compounds acting at the centrosome
US7468383B2 (en) 2005-02-11 2008-12-23 Cephalon, Inc. Proteasome inhibitors and methods of using the same
DE102005009784B4 (de) * 2005-03-03 2009-06-18 Technische Universität Darmstadt Peptid-Mimetika, Verfahren zur deren Herstellung, diese enthaltende pharmazeutische Zusammensetzung und deren Verwendung als Inhibitoren von Proteasomen und zur Induktion von Apoptose
MY171061A (en) 2005-11-09 2019-09-24 Onyx Therapeutics Inc Compounds for enzyme inhibition
CA2657213C (en) 2006-06-19 2017-01-03 Proteolix, Inc. Peptide epoxyketones for proteasome inhibition
KR20170125413A (ko) 2007-10-04 2017-11-14 오닉스 세라퓨틱스, 인크. 결정형 펩티드 에폭시 케톤 프로테아제 저해제 및 아미노산 케토-에폭시드의 합성
US9181296B2 (en) * 2008-03-26 2015-11-10 Novozymes A/S Stabilized liquid enzyme compositions
EP3090737A1 (en) 2008-10-21 2016-11-09 Onyx Therapeutics, Inc. Combination therapy with peptide epoxyketones
TWI504598B (zh) 2009-03-20 2015-10-21 Onyx Therapeutics Inc 結晶性三肽環氧酮蛋白酶抑制劑
US8853147B2 (en) 2009-11-13 2014-10-07 Onyx Therapeutics, Inc. Use of peptide epoxyketones for metastasis suppression
AU2010341530B2 (en) 2009-12-22 2016-03-10 Cephalon, Inc. Proteasome inhibitors and processes for their preparation, purification and use
EP2542238B1 (en) 2010-03-01 2015-08-12 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
NZ602872A (en) 2010-04-07 2014-05-30 Onyx Therapeutics Inc Crystalline peptide epoxyketone immunoproteasome inhibitor
CN104126017A (zh) 2011-11-11 2014-10-29 米伦纽姆医药公司 对蛋白酶体抑制剂的反应的生物标记
JP5540340B2 (ja) * 2012-02-29 2014-07-02 独立行政法人理化学研究所 炎症性疾患の判定方法
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
EP3936137A1 (en) 2013-02-07 2022-01-12 The General Hospital Corporation Methods for expansion or depletion of t-regulatory cells
CN111879948A (zh) 2013-10-17 2020-11-03 综合医院公司 鉴定响应于用于自身免疫性疾病的治疗的受试者的方法以及用于治疗该疾病的组合物
CN115043943A (zh) 2015-05-15 2022-09-13 综合医院公司 拮抗性抗肿瘤坏死因子受体超家族抗体
US20190135929A1 (en) 2015-08-28 2019-05-09 The General Hospital Corporation Agonistic anti-tumor necrosis factor receptor 2 antibodies
EP3355914B1 (en) 2015-09-29 2024-03-06 The General Hospital Corporation A composition comprising bcg for reducing cholesterol.
US11859002B2 (en) 2016-05-13 2024-01-02 The General Hospital Corporation Antagonistic anti-tumor necrosis factor receptor 2 antibodies
CN113302205B (zh) 2018-11-15 2024-12-06 综合医院公司 激动性肿瘤坏死因子受体超家族多肽
CN116997560A (zh) * 2020-11-24 2023-11-03 普罗基莱弗公司 用于治疗包膜病毒感染的化合物
KR20230156016A (ko) * 2020-11-24 2023-11-13 프로게라이프 분절성 프로제로이드 증후군 치료용 화합물

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4510130A (en) 1983-05-20 1985-04-09 Genetic Diagnostics Corporation Promoting animal and plant growth with leupeptin
US6410516B1 (en) 1986-01-09 2002-06-25 President & Fellows Of Harvard College Nuclear factors associated with transcriptional regulation
SE8702550D0 (sv) 1987-06-18 1987-06-18 Anders Grubb Cysteinproteashemmare
WO1989008147A1 (en) 1988-03-01 1989-09-08 Whitehead Institute For Biomedical Research ACTIVITION OF NF-kB PRECURSOR
ZA897515B (en) 1988-10-07 1990-06-27 Merrell Dow Pharma Novel peptidase inhibitors
JP2701932B2 (ja) 1989-04-10 1998-01-21 サントリー株式会社 タンパク質分解酵素阻害剤
AU661270B2 (en) 1990-03-05 1995-07-20 Cephalon, Inc. Chymotrypsin-like proteases and their inhibitors
CA2098609A1 (en) 1990-12-28 1992-06-29 Raymond T. Bartus Use of calpain inhibitors in the inhibition and treatment of neurodegeneration
WO1992012140A1 (en) 1990-12-28 1992-07-23 Georgia Tech Research Corporation Peptides ketoamides, ketoacids, and ketoesters
WO1992013549A1 (en) * 1991-02-07 1992-08-20 Research Corporation Technologies, Inc. Inhibition of cell proliferation by hydrophobic peptides
EP0504938A3 (en) * 1991-03-22 1993-04-14 Suntory Limited Prophylactic and therapeutic agent for bone diseases comprising di- or tripeptide derivative as active ingredient
AU2140592A (en) 1991-05-17 1992-12-30 Chiron Corporation Inhibitor of nf-kappa b transcriptional activator and uses thereof
EP0650368A1 (en) * 1992-06-24 1995-05-03 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of medical conditions associated with increased calpain activity
DE4311835A1 (de) 1993-04-07 1994-10-13 Boehringer Ingelheim Int Verfahren zur Inhibierung der Transkription von Genen
US5693617A (en) * 1994-03-15 1997-12-02 Proscript, Inc. Inhibitors of the 26s proteolytic complex and the 20s proteasome contained therein
KR970060809A (ko) * 1996-01-19 1997-08-12 김광호 자동응답전화기에서 예약 시각에 등록 음성메세지 전송 방법

Also Published As

Publication number Publication date
SI0750507T1 (en) 2003-04-30
DE69528888T3 (de) 2006-10-05
EP0750507B1 (en) 2002-11-20
SI0750507T2 (sl) 2006-08-31
ATE228002T1 (de) 2002-12-15
ES2182897T5 (es) 2006-10-16
DE69528888D1 (de) 2003-01-02
DK0750507T3 (da) 2003-02-17
EP0750507B2 (en) 2006-03-01
DK0750507T4 (da) 2006-07-03
JPH09510710A (ja) 1997-10-28
US6660268B1 (en) 2003-12-09
WO1995025533A1 (en) 1995-09-28
AU682264B2 (en) 1997-09-25
PT750507E (pt) 2003-04-30
US20040097420A1 (en) 2004-05-20
AU2121595A (en) 1995-10-09
CA2184727C (en) 2007-08-28
EP0750507A1 (en) 1997-01-02
EP0750507A4 (en) 1999-03-31
CA2184727A1 (en) 1995-09-28
DE69528888T2 (de) 2003-10-23

Similar Documents

Publication Publication Date Title
ES2182897T3 (es) Regulacion por proteasoma de la actividad de nf-kappa-b.
MX9703063A (es) Compuestos de ester y acido boronico, su sintesis y usos.
ES2001770A6 (es) Un metodo para limpiar y desinfectar simultaneamente lentes de contacto
ID24398A (id) Metode untuk menghasilkan asam l-amino
ES2054649T3 (es) 2-aminotetralinas basicas substituidas.
YU99092A (sh) Organske soli n,n'-diacetilcistina i postupak za njihovo dobijanje
ES2181845T3 (es) Uso de tomoxetina para el tratamiento de la hiperactividad inducida por trastornos de la atencion.
DE50010931D1 (de) Substituierte benzimidazole
ES2132678T3 (es) Sal de nimesulido hidrosoluble y su utilizacion para el tratamiento de las afecciones inflamatorias.
ES2159851T3 (es) Amidas de acidos aminotiofenocarboxilicos y su empleo como inhibidores de la fosfodiestearasa.
DE3887375D1 (de) Pflanzengewebe-Transformation.
ES2052831T3 (es) Procedimiento para la obtencion de sulfonamidas del acido tetrahidro-1-benzo (c,d)-indol-propionilo.
ES2129423T3 (es) Vacunas.
ES2102984T3 (es) Medios para el crecimiento de celulas y procedimiento para preparar los mismos.
ES2089687T3 (es) 4-fenil-piridonas y 4-fenil-2-alcoxipiridinas sustituidas como inhibidores de la hmg-coa-reductasa.
ES2079438T3 (es) Lubricante esterilizable.
ES2058343T3 (es) Piridinas disubstituidas.
ES2157690T3 (es) Metodo de producir el nivel de potencia recibido en una estacion base de una red cdma y estacion base para su ejecucion.
ES2127424T3 (es) Procedimiento para la fabricacion de poliuretanos y/o poliuretanoureas, en su caso, celulares.
MX9200977A (es) Proceso para producir l-lisina por fermentacion.
ES2155152T3 (es) Aminometilcromanos sustituidos por benzoisotiazolilo.
MX9500295A (es) Metodo y circuito para mantener la carga en una bateria de respaldo.
ES2077674T3 (es) Aumento de la produccion de proteinas en animales.
DE60035515D1 (de) Hohe zytokinproduktion mit verbesserte zelllebensfähigkeit
BG46905A3 (bg) Метод за получаване на полицикличен етерен антибиотик